[go: up one dir, main page]

AR032629A1 - Compuestos derivados de imidazol y composicion farmaceutica que los contiene - Google Patents

Compuestos derivados de imidazol y composicion farmaceutica que los contiene

Info

Publication number
AR032629A1
AR032629A1 ARP010103637A ARP010103637A AR032629A1 AR 032629 A1 AR032629 A1 AR 032629A1 AR P010103637 A ARP010103637 A AR P010103637A AR P010103637 A ARP010103637 A AR P010103637A AR 032629 A1 AR032629 A1 AR 032629A1
Authority
AR
Argentina
Prior art keywords
straight
branched chain
membered
nr7r8
independently selected
Prior art date
Application number
ARP010103637A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR032629A1 publication Critical patent/AR032629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Un compuesto por ser de formula (1) en la que: R1 es alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14, o heteroarilo de 5-14 miembros; y estando R1 opcionalmente sustituido con 1-6 sustituyentes R5 seleccionados independientemente entre F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7C(=O)NR8R, -NR7S(=O)2R8, -NR7S(=O)2R8R9, -OR7, -OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, -O-S(=O)2R7, N3 y R7; R2 es H, F, -CH3, -CN o -C(=O)OR7; R3 es -C(=O)NR9, -C(=O)O-, -C(=O)(CR10R11)n-, o -(CR10R11)n-; R4 es alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 o heteroarilo de 5-14 miembros, estando R4 opcionalmente sustituido con 1-3 sustituyentes R6 seleccionados independientemente entre F, Cl, Br, I, nitro, ciano, -CF3, -NR7R8, -NR7C(=O)R8, -NR7C(=O)OR8, -NR7C(=O)NR8R9, -NR7S(=O)2R8, -NR7S(=O)2NR8R9, -OR7, -OC(=O)R7, -OC(=O)OR7, -C(=O)OR7, -C(=O)R7, -C(=O)NR7R8, -OC(=O)NR7R8, -OC(=O)SR7, -SR7, -S(=O)R7, -S(=O)2R7, -S(=O)2NR7R8, o R7; cada uno de R7, R8 y R9 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R7, R8 y R9 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR10R11, -NR10C(=O)R11, -NR10C(=O)OR11, -NR10C(=O)NR11R12, -NR10S(=O)2R11, -NR10S(=O)2NR11R12, -OR10, -OC(=O)R10, -OC(=O)OR10, -OC(=O)NR10R11, -OC(=O)SR10, -SR10, -S(=O)R10, -S(=O)2R10, -S(=O)2NR10R11, -C(=O)R10, -C(=O)OR10, -C(=O)NR10R11 y R10; o, cuando R7 y R8 son como en NR7R8, pueden estar unidos opcionalmente para formar, junto con el nitrogeno de NR7R8 al que están unidos, un resto heterocicloalquilo de 3-7 miembros de anillo, comprendiendo opcionalmente dicho resto heterocicloalquilo 1-2 heteroátomos adicionales seleccionados independientemente entre N, O y S; cada uno de R10, R11 y R12 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R10, R11 y R12 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR13R14, -NR13C(=O)R14, -NR13C(=O)OR14, -NR13C(=O)NR14R15, -NR13S(=O)2R14, -NR13S(=O)2NR14R15, -OR13, -OC(=O)R13, -OC(=O)OR13, -OC(=O)NR13R14, -OC(=O)SR13, -SR13, -S(=O)R13, -S(=O)2R13, -S(=O)2NR13R14, -C(=O)R13, -C(=O)OR13, -C(=O)NR13R14 y R13; cada uno de R13, R14 y R15 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-14 y heteroarilo de 5-14 miembros, estando cada uno de R13, R14 y R15 opcional e independientemente sustituido con 1-6 sustituyentes seleccionados entre F, Cl, Br, I, NO2, -CN, -CF3, -NR16R17, -NR16C(=O)R17, -NR16C(=O)OR17, -NR16C(=O)NR17R18, -NR16S(=O)2R17, -NR16S(=O)2NR17R18, -OR16, -OC(=O)R16, -OC(=O)OR16, -OC(=O)NR16R17, -OC(=O)SR16, -SR16, -S(=O)R16, -S(=O)2R16, -S(=O)2NR16R17, -C(=O)R16, -C(=O)OR16, -C(=O)NR16R17 y R16; cada uno de R16, R17 y R18 se selecciona independientemente entre H, alquilo C1-8 de cadena lineal o ramificada, alquenilo C2-8 de cadena lineal o ramificada, alquinilo C2-8 de cadena lineal o ramificada, cicloalquilo C3-8, cicloalquenilo C4-8, heterocicloalquilo de 3-8 miembros, bicicloalquilo C5-11, bicicloalquenilo C7-11, heterobicicloalquilo de 5-11 miembros, arilo C6-13 y heteroarilo de 5-12 miembros; n es 0, 1, 2 o 3; siendo R10 y R11 en -C(=O)(CR10R11)n- y -(CR10R11)n-, para cada repeticion de n, independientemente como se ha mencionado anteriormente; o una sal farmacéuticamente aceptable del mismo. Se indica que los compuestos de formula (1) tienen actividad inhibidora de cdk5, cdk2 y GSK-3. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de formula (1) para tratar y prevenir enfermedades y afecciones que comprenden un crecimiento celular anormal, tal como el cáncer, enfermedades y afecciones neurodegenerativas, y las afectadas por la neurotransmision de dopamina. También se describen composiciones farmacéuticas y procedimientos que comprenden compuestos de formula (1) para tratar la fertilidad masculina y motilidad de los espermatozoides; diabetes mellitus; disminucion de la tolerancia a la glucosa; síndrome metabolico o síndrome X; síndrome de ovarios poliquísticos; adipogénesis y obesidad; miogénesis y debilidad, por ejemplo, la reduccion del rendimiento físico relacionado con la edad; sarcopenia aguda, por ejemplo, atrofia muscular y/o caquexia asociada con quemaduras, reposo en cama, inmovilizacion de miembros o cirugía torácica, abdominal y/u ortopédica mayor; sepsis; pérdida del cabello, debilitamiento del cabello y calvicie; e inmunodeficiencia.
ARP010103637A 2000-07-31 2001-07-30 Compuestos derivados de imidazol y composicion farmaceutica que los contiene AR032629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22172400P 2000-07-31 2000-07-31

Publications (1)

Publication Number Publication Date
AR032629A1 true AR032629A1 (es) 2003-11-19

Family

ID=22829075

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103637A AR032629A1 (es) 2000-07-31 2001-07-30 Compuestos derivados de imidazol y composicion farmaceutica que los contiene

Country Status (35)

Country Link
EP (1) EP1305295A1 (es)
JP (2) JP4166084B2 (es)
KR (1) KR20030019644A (es)
CN (1) CN1444567A (es)
AP (1) AP2001002232A0 (es)
AR (1) AR032629A1 (es)
AU (1) AU2001270944A1 (es)
BG (1) BG107469A (es)
BR (1) BR0112862A (es)
CA (1) CA2418115A1 (es)
CR (1) CR6861A (es)
CZ (1) CZ2003225A3 (es)
DO (1) DOP2001000220A (es)
EA (1) EA200300097A1 (es)
EC (1) ECSP034445A (es)
EE (1) EE200300049A (es)
GT (1) GT200100147A (es)
HR (1) HRP20030048A2 (es)
HU (1) HUP0303069A3 (es)
IL (1) IL153787A0 (es)
IS (1) IS6662A (es)
MA (1) MA26932A1 (es)
MX (1) MXPA03000939A (es)
NO (1) NO20030472L (es)
NZ (1) NZ523272A (es)
OA (1) OA12345A (es)
PA (1) PA8523701A1 (es)
PE (1) PE20020337A1 (es)
PL (1) PL365134A1 (es)
SK (1) SK1042003A3 (es)
SV (1) SV2002000571A (es)
TN (1) TNSN01114A1 (es)
UY (1) UY26862A1 (es)
WO (1) WO2002010141A1 (es)
ZA (1) ZA200300819B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2003106455A1 (en) 2002-06-14 2003-12-24 Applied Research Systems Ars Holding N.V. Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
ES2288694T3 (es) 2003-05-20 2008-01-16 Bayer Pharmaceuticals Corporation Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas.
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
GEP20084420B (en) * 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
WO2006033446A1 (en) 2004-09-21 2006-03-30 Astellas Pharma Inc. Aminoalcohol derivatives
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
CN101282941A (zh) 2005-09-22 2008-10-08 辉瑞产品公司 用于治疗神经障碍的咪唑类化合物
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EA200801716A1 (ru) 2006-01-18 2009-04-28 Амген Инк. Тиазольные соединения и их применение
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2666590C (en) 2006-10-21 2015-10-06 Abbott Gmbh & Co. Kg Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2010011663A (es) * 2008-04-24 2011-01-21 Abbott Gmbh & Co Kg Derivados de 1-(7-hexahidropirrolo [3,4-c] pirrol-2 (1h)-il) quinolin-3-il)-(pirazin-2-il) urea y compuestos relacionados como glicogeno sintasa quinasa 3 (gsk-3).
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2928474B1 (en) 2012-12-07 2018-11-14 ChemoCentryx, Inc. Diazole lactams
DK2935227T3 (en) * 2012-12-21 2017-12-04 Chemocentryx Inc DIAZOLAMIDES AS CCR1 RECEPTOR ANTAGONISTS
EP3103455A4 (en) * 2014-02-07 2017-10-04 National University Corporation Tokyo Medical and Dental University Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
AU2016317046B2 (en) * 2015-08-31 2022-03-10 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
CN109310677A (zh) 2016-04-07 2019-02-05 凯莫森特里克斯股份有限公司 通过联合施用ccr1拮抗剂与pd-1抑制剂或pd-l1拮抗剂降低肿瘤负荷
CN111018840B (zh) * 2017-10-25 2022-09-09 西南大学 3-咪唑取代的靛红唑醇类化合物及其制备方法和医药应用
US20210236466A1 (en) * 2018-07-03 2021-08-05 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020163812A1 (en) 2019-02-08 2020-08-13 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
FI4010322T3 (fi) 2019-08-09 2025-12-16 Pfizer (s)-2-(((s)-6,8-difluori-1,2,3,4-tetrahydronaftalen-2-yyli)amino)-n-(1-(2-metyyli-1-(neopentyyliamino)propan-2-yyli)-1h-imidatsol-4-yyli)pentaaniamidin kiinteitä olomuotoja ja niiden käyttö
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
WO2022079290A2 (en) * 2020-10-16 2022-04-21 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Cullin ring ubiquitin ligase compounds and uses thereof
CN112250636A (zh) * 2020-11-09 2021-01-22 广西科技大学 5-氨基咪唑类化合物及其合成方法
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
IL311128A (en) 2021-09-01 2024-04-01 Springworks Therapeutics Inc Synthesis of neurogestate
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
CN116983313B (zh) * 2023-07-13 2026-01-27 四川大学 Nu6300的新用途
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ATE274510T1 (de) * 1998-06-19 2004-09-15 Chiron Corp Glycogen synthase kinase 3 inhibitoren
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
EP1106180B1 (en) * 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments

Also Published As

Publication number Publication date
HUP0303069A3 (en) 2004-04-28
ECSP034445A (es) 2003-03-10
JP2008255123A (ja) 2008-10-23
MXPA03000939A (es) 2003-06-24
SK1042003A3 (en) 2004-05-04
AU2001270944A1 (en) 2002-02-13
ZA200300819B (en) 2004-04-20
BG107469A (bg) 2003-09-30
PE20020337A1 (es) 2002-05-08
CR6861A (es) 2004-03-11
UY26862A1 (es) 2002-02-28
IL153787A0 (en) 2003-07-31
GT200100147A (es) 2002-06-25
OA12345A (en) 2004-04-13
NZ523272A (en) 2004-08-27
CN1444567A (zh) 2003-09-24
MA26932A1 (fr) 2004-12-20
SV2002000571A (es) 2002-10-24
DOP2001000220A (es) 2002-05-15
PA8523701A1 (es) 2002-04-25
HUP0303069A2 (hu) 2004-03-01
EP1305295A1 (en) 2003-05-02
NO20030472D0 (no) 2003-01-30
KR20030019644A (ko) 2003-03-06
JP2004505111A (ja) 2004-02-19
JP4166084B2 (ja) 2008-10-15
BR0112862A (pt) 2003-07-01
EE200300049A (et) 2004-10-15
PL365134A1 (en) 2004-12-27
HRP20030048A2 (en) 2003-04-30
CZ2003225A3 (cs) 2004-02-18
IS6662A (is) 2002-12-19
EA200300097A1 (ru) 2003-06-26
WO2002010141A1 (en) 2002-02-07
TNSN01114A1 (fr) 2005-11-10
NO20030472L (no) 2003-03-27
CA2418115A1 (en) 2002-02-07
AP2001002232A0 (en) 2001-09-30

Similar Documents

Publication Publication Date Title
AR032629A1 (es) Compuestos derivados de imidazol y composicion farmaceutica que los contiene
AR035345A1 (es) Compuestos derivados de pirazol, composicion farmaceutica, compuestos intermediarios
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR062469A1 (es) Compuestos de azabenzotiofeno y azabenzofurano como inhibidores de la quinasa mek, una composicion farmaceutica que los comprende y el uso de estos en el tratamiento de trastornos inflamatorios e hiperproliferativos.
CA2437524A1 (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
AR035436A1 (es) Una benzofenona o derivado farmaceuticamente aceptable, sales, formas salinas, composiciones farmaceuticas, usos para la fabricacion de un medicamento, y proceso para la preparacion de una benzofenona
AR064345A1 (es) Derivados de 8-oxoadenina
AR019789A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
AR057979A1 (es) PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
AR035087A1 (es) Piridil-alquinos y piridil-n-oxido-alquinos herbicidas activos, procedimiento para su preparacion, composicion herbicida y para inhibir el crecimiento de plantas, metodo para el control del crecimiento de plantas indeseables , y metodo para la inhibicion del crecimiento de plantas
AR056199A1 (es) Derivados de 8-oxoadenina 9-sustituida
AR049124A1 (es) Compuestos de de pirimidinona como inhibidores de la integrasa del virus hiv, composiciones farmaceuticas que las contienen y su uso en el tratamiento del sida y de la infeccion por hiv
AR069637A1 (es) Derivados de pirazinas
AR072092A1 (es) Diazacarbazoles y metodos de uso
ECSP099437A (es) Composición herbicida
ES2572189T3 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
NO20083520L (no) Tricykliske N-heteroaryl-karboksamidderivater inneholdende en benzimidazolenhet, fremgangsmate for fremstilling av samme og deres terapeutiske anvendelser
JOP20200338A1 (ar) عامل وقائي أو علاجي للضمور العضلي نخاعي المنشأ
ES2570127T3 (es) Compuestos y composiciones como inhibidores de la proteína quinasa
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
AR074474A1 (es) Inhibidores ns5a de vhc
AR063800A1 (es) Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos
AR073739A1 (es) Aminopirimidinas como inhibidores de los receptores de histamina
AR052863A1 (es) Compuestos de quinolina heteroaromaticos

Legal Events

Date Code Title Description
FB Suspension of granting procedure